Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients
Acta Neuropsychiatrica · 2024
DOI: 10.1017/neu.2024.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropsychiatrica, 2024. Verfasst von Hanna Puolakka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Clozapine, Polymorphism, Single Nucleotide, Antipsychotic Agents, Receptor, ErbB-4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Sialorrhea is a common and uncomfortable adverse effect of clozapine, and its severity varies between patients. The aim of the study was to select broadly genes related to the regulation of salivation and study associations between sialorrhea and dry mouth and polymorphisms in the selected genes.
Methods
The study population consists of 237 clozapine-treated patients, of which 172 were genotyped. Associations between sialorrhea and dry mouth with age, sex, BMI, smoking, clozapine dose, clozapine and norclozapine serum levels, and other comedication were studied. Genetic associations were analyzed with linear and logistic regression models explaining sialorrhea and dry mouth with each SNP added separately to the model as coefficients.
Results
Clozapine dose, clozapine or norclozapine concentration and their ratio were not associated with sialorrhea or dryness of mouth. Valproate use ( p = 0.013) and use of other antipsychotics ( p = 0.015) combined with clozapine were associated with excessive salivation. No associations were found between studied polymorphisms and sialorrhea. In analyses explaining dry mouth with logistic regression with age and sex as coefficients, two proxy-SNPs were associated with dry mouth: epidermal growth factor receptor 4 (ERBB4) rs3942465 (adjusted p = 0.025) and tachykinin receptor 1 (TACR1) rs58933792 (adjusted p = 0.029).
Conclusion
Use of valproate or antipsychotic polypharmacy may increase the risk of sialorrhea. Genetic variations in ERBB4 and TACR1 might contribute to experienced dryness of mouth among patients treated with clozapine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Department of Psychiatry, The Pirkanmaa Wellbeing Services County, Tampere, Finland.
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Department of Psychiatry, The Wellbeing Services County of Ostrobothnia, Seinäjoki, Finland.
- Department of Psychiatry, Satasairaala Hospital, The Satakunta Wellbeing Services County, Pori, Finland.
- Department of Psychiatry, Department of Clinical Sciences (Psychiatry), Faculty of Medicine, University Hospital of Umeå, Umeå University, Umeå, Sweden.
ORCID-Profile: Hanna Puolakka, Olli Kampman
Zitieren
APA
Puolakka, H., Solismaa, A., Lyytikäinen, L. P., Viikki, M., Seppälä, N., Mononen, N., Lehtimäki, T., & Kampman, O. (2024). Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2024.9
Vancouver
Puolakka H, Solismaa A, Lyytikäinen LP, Viikki M, Seppälä N, Mononen N, et al. Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients. Acta Neuropsychiatrica. 2024. doi:10.1017/neu.2024.9
BibTeX
@article{Puolakka2024,
author = {Puolakka, Hanna and Solismaa, Anssi and Lyytikäinen, Leo-Pekka and Viikki, Merja and Seppälä, Niko and Mononen, Nina and Lehtimäki, Terho and Kampman, Olli},
title = {Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients},
journal = {Acta Neuropsychiatrica},
year = {2024},
doi = {10.1017/neu.2024.9}
}
EUVIMED